Results 71 to 80 of about 31,702 (234)

Prosthesis survival situation and complications following total hip arthroplasty in hemophilic patients: a systematic review

BMC Musculoskeletal Disorders
Background Hemophilic arthropathy, resulting from recurrent joint bleeding in patients with hemophilia, often necessitates total hip arthroplasty (THA) to alleviate pain and improve joint function.
Lei Chen, Shineng Lin, Wenlu Zhou, Yiqing Ling, Zhenyu Shi, Qinwen Ge, Wenbin Liu, Ju Li, Peijian Tong, Huihui Li, Taotao Xu   +10 more
doaj   +1 more source

The Swiss Haemophilia Registry–Report From the First 8 Years

Haemophilia, EarlyView.
ABSTRACT Introduction Patient registries capture disease related information and provide a valuable source for real‐world data on rare diseases and their management. The Swiss Haemophilia Registry (SHR) was established in 2015 on the basis of a new Swiss federal human research act.
Alessandra Bosch, Lorenzo Alberio, Pierre Fontana, Lukas Graf, Johanna A. Kremer Hovinga, Nicolas von der Weid, Mattia Rizzi, Manuela Albisetti, the Swiss Haemophilia Network   +8 more
wiley   +1 more source

Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study)

Research and Practice in Thrombosis and Haemostasis
Background: The impact of nonneutralizing antibodies (NNAs) in moderate hemophilia is elusive. Objectives: To explore the presence of NNAs in Nordic persons with moderate hemophilia A (MHA) and B (MHB) in relation to treatment modality, clinical outcome,
Ragnhild J. Måseide, MD, PhD, Erik Berntorp, MD, PhD, Jan Astermark, MD, PhD, Anna Olsson, MD, PhD, Maria Bruzelius, MD, PhD, Tony Frisk, MD, PhD, Vuokko Nummi, MD, PhD, Riitta Lassila, MD, PhD, Karin Strandberg, MD, PhD, Geir E. Tjønnfjord, MD, PhD, Pål A. Holme, MD, PhD   +10 more
doaj   +1 more source

Monitoring Extended Half‐Life Factor VIII and IX Concentrates: Performance in Routine Clotting‐and Thrombin Generation Assays

Haemophilia, EarlyView.
ABSTRACT Introduction Monitoring extended half‐life (EHL) factor (F) VIII and FIX products is complex, as discrepant results are obtained in different laboratory assays. Aim To provide an overview on assay accuracy based on a re‐assessment of previously published data as well as laboratory results of EHL spiking experiments for specific factor assays ...
An K. Stroobants, Eva‐Leonne Göttgens, Yvonne M. C. Henskens, Joop H. Jansen, Saskia E. M. Schols, Sanna R. Rijpma   +5 more
wiley   +1 more source

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

Haemophilia, EarlyView.
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima, Katsuyuki Fukutake, Yoshiyuki Ogawa, Yuta Kamei, Chiaki Sugita, Akinori Yuri, Ryota Kobayashi, Akiko Ioka, Tadashi Matsushita   +8 more
wiley   +1 more source

Challenges in prophylactic therapy with Emicizumab in patients with hemophilia A: Focus on monitoring tests

Romanian Journal of Laboratory Medicine
This study presents a transversal investigation that we performed at Fundeni hospital (Bucharest, Romania) into the therapeutic benefits and efficacy of Emicizumab, a non-factor therapy, in the context of hemophilia A.
Brinza Melen, Uscatescu Valentina, Hemcinschi Mihai, Chiriac Elisabeta, Gherghe Georgiana, Coriu Daniel   +5 more
doaj   +1 more source

Strategies for Hemophilia Treatment, a literature review of current evidence

مجله دانشگاه علوم پزشکی بیرجند, 2023
Hemophilia is an inherited bleeding disorder caused by malfunctioning or lacking blood coagulation factor VIII (hemophilia A) or IX (hemophilia B). Currently, the main treatments for these X-linked diseases are replacement therapy using periodic and ...
Fahimeh Ghasemi, Nafiseh Erfanian, Samira Karbasi, Alireza Zomorodipour   +3 more
doaj  

Seventh Åland Island Meeting on von Willebrand Disease

Haemophilia, EarlyView.
ABSTRACT Introduction The seventh Åland Island Meeting on von Willebrand Disease (VWD) was held on the Åland archipelago in Finland, from 26 to 28 September 2024. Aim The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD.
Riitta Lassila, Ruben Bierings, Nathan T. Connell, Fernando F. Corrales‐Medina, Augusto B. Federici, Veronica H. Flood, Floor Heubel‐Moenen, Jill M. Johnsen, Geoffrey Kuppens, Davide Matino, Carolyn Millar, Ingmar Schoen, Anish Sharda, Robert F. Sidonio Jr, Alok Srivastava, Timea Szanto, Angela C. Weyand, Erik Berntorp   +17 more
wiley   +1 more source

Real‐world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center

Pediatric Investigation
Importance Emicizumab (EMI) is efficacious and safe for hemophilia A (HA) prophylaxis. However, its high cost poses a challenge in China. Objective To explore the possibility of using reduced‐dosage EMI in Chinese HA children.
Qianqian Mao, Zhenping Chen, Guoqing Liu, Gang Li, Yingzi Zhen, Xiaoling Cheng, Zekun Li, Wanru Yao, Di Ai, Zhengping Li, Nan Wang, Man‐Chiu Poon, Runhui Wu   +12 more
doaj   +1 more source

Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects

TH Open, 2019
Background Recombinant (rec-) coagulation factor VIII concentrates available for hemophilia A (HA) treatment differ in cell line production and structure, which could affect their pharmacodynamics and immunogenicity.
Raimondo De Cristofaro, Monica Sacco, Stefano Lancellotti, Federico Berruti, Isabella Garagiola, Carla Valsecchi, Maria Basso, Enrico Di Stasio, Flora Peyvandi   +8 more
doaj   +1 more source